Abstract. Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/ neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni-or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible.
Introduction
There are four members of the EGFR family of receptors, each of which is capable of forming heterodimers with other family members. These members are EGFR (erbB1, HER1), HER2 (erbB2/neu), erbB3 (HER3), and erbB4 (HER4).
The discovery that some women with early-stage breast cancer overexpress HER2 has led to the development of the recombinant humanized monoclonal antibody trastuzumab (Herceptin ® ; Genentech, San Francisco, CA). Trastuzumab is actually indicated for patients with tumors that overexpress HER2 and has an excellent therapeutic index, with consistent evidence that it improves the efficacy of available therapies in all stages of breast cancer, both in adjuvant and in metastatic settings (1, 2) . ONCOLOGY REPORTS 25: 1545 -1548 , 2011 Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients DANIELE Nuclear factor-κB (NF-κB), a transcription factor with pleotropic effects, is a downstream mediator of growth signaling in erbB2 (HER-2/neu) receptor-positive cancer and activation of NF-κB in human breast cancer is confined predominately to those that express members of the EGF family of receptors, including the EGF receptor (erbB1) and erbB2 (4) . The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy (5) . Infact, preliminary results also revealed that specific inhibitors of NF-κB and the EGFR family of cell surface receptors in combinations have demonstrated to block proliferation synergistically at concentrations which are ineffective when used individually (6) . Preclinical data revealed that 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine, was able to stimulate the proliferation of SW1116 colon cancer cell line enhancing NF-κB DNA binding activity (7) . Moreover, nicotine, the major alcaloid in tobacco, increases the oxidative stress of colon cancer cells, leading to the activation of NF-κB, a redox-sensitive trascription factor (8) and promotes colon cancer cell proliferation and tumor growth in a dose-dependent manner, increasing EGFR phosphorylation levels (9) .
Drawing from the above considerations, our group has evaluated the impact of cigarettes smoking on trastuzumab efficacy in a large cohort of metastatic breast cancer patients treated with trastuzumab-based regimens as first line of therapy.
Materials and methods
Women with pathologically confirmed, uni-or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) not treated with any drug for metastatic disease were considered eligible. Patients were required to be ≥18 years of age, have an Eastern Cooperative Oncology Group performance status of 0-2. Patients with samples scoring 3+ by IHC or positive by FISH were eligible, whereas those with a 2+ IHC score also had to have a positive result by FISH. Patients who had received prior chemotherapy for MBC were excluded although prior adjuvant or neoadjuvant chemotherapy was permitted. Concurrent chemotherapy or hormonal therapy was allowed. Patients with brain metastasis not responding to treatment were excluded. At least 4 weeks were required to elapse between last surgery or radiation therapy with full recovery, and indicator lesions had to be outside prior radiation fields.
We considered all consecutive patients for whom data on smoking habit were detectable from medical records between 2004 Treatment plan. Trastuzumab was administered according to different schedules (weekly or three-weekly, after induction) and in association with different cytotoxic agents. Tumor response was evaluated every 9 weeks using consistent imaging techniques (CT or MRI). Response assessment was performed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST).
Statistical analysis.
We conducted the present cohort study to evaluate whether active or passive cigarettes smoking status affects time to progression (TTP) and overall survival (OS) among MBC patients treated with chemotherapy plus cetuximab. TTP was calculated from the date of starting trastuzumab-based treatment to the first observation of disease progression or to death from any cause, occurring within 60 days after the start of treatment or the most recent tumor assessment. OS time was calculated from the date of starting trastuzumab-based treatment until death from any cause or until the date of the last follow-up, at which point data were censored. The Kaplan-Meier product-limit method was used for analysis of TTP and OS (10) .
Moreover, the differences in terms of TTP and OS between different groups were evaluated by the log-rank test (11) . The cut-off point for survival data was July 2008; for safety data, it was March 2007. SPSS software (version 13.05, SPSS, Chicago, IL) was used for statistical analysis. A P<0.05 was considered to indicate statistical significance.
Results
We retrospectively analysed the smoking habits of 248 MBC patients (median age 56 years, range 28-86 years) treated with different anticancer regimens (paclitaxel-and docetaxel-based: 210 patients; vinorelbine-based: 27 patients; anthracyclinebased; 5 patients; carboplatin-based: 6 patients) plus trastuzumab. Table I lists the patient characteristics.
We characterized the following three groups: never smokers, former smokers (patients who had given up smoking at least 6 months before the beginning of trastuzumab-based treatment) and current smokers. Moreover, we further divided the last group in two sub-populations: patients smoking ≤10, ≥10 cigarettes per day. Data on passive smoking were collected. A passive smoker was defined as a person who usually breaths ambient air containing carcinogenic inhalants from an 'active' cigarette smoker at least for 2 h every day for not less than 10 years. We did not analyse cigar or pipe smoking.
As reported in Table I our population was composed of 169 never smokers, 33 former smokers and 46 active smokers, (20 ≤10 cigarettes/day, 26 >10 cigarettes/day). We included in this observational trial 59 passive smokers. There were no significant differences in terms of age, PS, hormonal receptor status, grading and trastuzumab-associated chemotherapy regimen among the three groups determined by their smoking habit (data not shown).
No statistically significant difference in terms of response rate (RR) and TTP has been identified between smokers (former plus active smokers) and never smokers. The RR in non-smokers was of 50.6% and in smokers was of 50% (P=0.736). Fig. 1 shows the median TTP was 15 months (95% CI: 12.42-17.58) vs. 14.1 (95% CI: 12.62-17.38) in non-smokers and smokers, respectively (P=0.683). Moreover, no statistically significant difference in terms of response rate (RR) and TTP has been identified also comparing active smokers and former smokers. In particular, the RR in former smokers was of 52 versus 42.2% in active smokers (P=0.462). Fig. 2 reports the median TTP was 15 months (95% CI: 12.54-17.45) vs. 16 (95% CI: 7.46-24.5) in former smokers and active smokers, respectively (P=0.581). We did not observe any significant statistical difference in term of TTP between smokers ≥10 cigarettes/day and <10 cigarettes/ day, with median values of 12 months (95% CI: 6.84-17.15) and 15 months (95% CI: 11.56-18.43), respectively as reported in Fig. 3 . In the same subgroups we evaluated the median values of overall survival. Also for overall survival no significant statistical differences have been observed when smokers versus non-smokers (P=0.636), active smokers and former smokers (P=0.431) and smokers of ≥10 cigarettes/day ONCOLOGY REPORTS 25: 1545-1548, 2011 Table I . Patient characteristics. and <10 cigarettes/day (P=0.998) were compared (survival curves not reported).
Discussion
This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/ neu-positive breast cancer patients. At the same time these results deserve to be confirmed prospectively in other adequately designed clinical trials, given the potentially relevant implications in the clinical practice. Our results could be undermined by the use of retrospectively collected smoking data, rather than data collected at the beginning of trastuzumab therapy.
It must be considered that smoking habits may change following a cancer diagnosis as well as during cancer treatment. Moreover, we did not observe any correlation between cigarette smoking habit and trastuzumab activity and efficacy considering the entire population. The number of hormonal receptor positive patients in our cohort was too low in order to investigate any significant correlation with trastuzumab activity in this subpopulation. Some additional biases should be taken in consideration and limit the reproducibility of the results presented in the present report. Data on smoking habit in our patients population were, at least partially, obtained retrospectively, performing a direct question to patients during a medical visit of by a phone call. This methodology could led to a selection bias excluding deceased patients possibly with a worst prognosis. This point could represent the reason of the longer TTP and OS observed in our analysis when compared with that observed with the same cancer population in published clinical trials (9) . On the contrary the observed response rate in the population of smokers vs. nonsmokers is reasonably reliable.
However, despite the constitutive NF-κB activation in some HER-2/neu positive breast cancer is a frequent genetic condition (4) (5) (6) (7) and it has been demonstrated that nicotine has a proliferative role on cancer cells through the PI3K/AKT pathway activation and the PTEN pathway inhibition (8,9), we may suppose that the potential role of nicotine in inducing resistance to trastuzumab therapy in MBC is overcome by other predominant molecular and/or genetic mechanisms conditioning the proliferation and invasive processes of cancer in the metastatic phase. With the same rational, the adjuvant setting of breast cancer appears to represent the best setting to analyse the potential detrimental effects of nicotine in trastuzumab based adjuvant therapy.
In conclusion, despite the potential methodological limits of the present retrospective study, the large number of included patients and the very accurate modality of cigarette habit data collection, allow us to strongly suggest the lack of any activity and efficacy interaction between smoke and trastuzumab based therapy in MBC.
